

Haematologica
HAEMATOL/2018/196931
Version 4

Mutations in RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia

Neus Giménez, Alejandra Martínez-Trillos, Arnau Montraveta, Mónica Lopez-Guerra, Laia Rosich, Ferran Nadeu, Juan G Valero, Marta Aymerich, Laura Magnano, Maria Rozman, Estella Matutes, Julio Delgado, Tycho Bauman, Eva Gine, Marcos González, Miguel Alcoceba, M Jose Terol, Blanca Navarro, Enrique Colado, Angel R Payer, Xose S Puente, Carlos López-Otín, Armando Lopez-Guillermo, Elias Campo, Dolors Colomer, and Neus Villamor

Disclosures: This study was supported by the Ministerio de Economía y Competitividad, Grant No. SAF2015-31242-R ,and PI16/00420 which are part of Plan Nacional de I+D+I and are co-financed by the ISCII-Sub-Directorate General for Evaluation and the European Regional Development Fund (FEDER-“Una manera de hacer Europa”). European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no. 306240. Generalitat de Catalunya Suport Grups de Recerca; 2017 SGR 1009, Spanish Ministry of Science and Innovation (MICINN) through the Instituto de Salud Carlos III (ISCIII) International Cancer Genome Consortium for Chronic Lymphocytic Leukemia (ICGC-CLL Genome Project), and project PM15/00007, which is part of Plan Nacional de I+D+I and are co-financed by the ISCII-Sub-Directorate General for Evaluation and the European Regional Development Fund (FEDER-“Una manera de hacer Europa”). Redes Temáticas de Investigación Cooperativa de Cáncer from the Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Economy and Competitiveness & European Regional Development Fund (ERDF) “Una manera de hacer Europa” RD12/0036/0004, RD12/0036/0023 and RD12/0036/0039, and CIBERONC.

Contributions: Conception and design: NV, DC, Development of methodology; performed research: NG, AMT, AM, MLG, LR, FN, JD Acquired and managed samples: MA, LM, MR, TB, EG, MG, MA, MJT, BN, EC, ARP, Analysis and interpretation of data: NG, ALT, AM, JGV, DC, NV, MLG, JD Writing: ALT, NG, DC, NV Review of the manuscript: EM, JD, MG, EM, ALG, XSP, CLO, Study supervision: DC, NV